• Journal of Korean Neurosurgical Society
• /
• 제38권6호
• /
• pp.450-455
• /
• 2005

Objective : Pituitary apoplexy is a rare clinical syndrome caused by pituitary hemorrhage, hemorrhagic infarction, or ischemic infarction within a pituitary tumor or surrounding structure. We analyzed surgical outcomes of pituitary apoplexy. Methods : From 1995 to 2004, we reviewed our experience of 29 cases with pituitary apoplexy. In all patients, pre- and postoperative clinical presentation were checked and endocrine study were performed. Results : The most frequent symptoms were visual disturbance [24 cases, 82.8%] and headache [22 cases, 75.9%]. After surgery, headache improved in 86.4%, 88.9% among 18cases who had preoperative reduction in visual acuity and 75.0% among 12 cases who had preoperative reduction in visual field improved. In endocrine study, long-term steroid and thyroid hormone replacement therapy was necessary in 42.9% of 14 cases presenting preoperative hypopituitarism. Postoperative transient hypopituitarism developed in 5 cases [33.3%] and they all recovered in follow up study. Postoperative endocrinological recovery were in 77.9% of 9 cases with preoperative prolactinoma, 1 case in 2 cases with acromegaly and one case with Cushing disease. Postoperative complications were diabetes inspidus[DI] in 1 case [3.4%]. cerebrospinal fluid[CSF] leakage in 2 cases [6.8%] and death in 1 case [3.4%] due to sepsis, Conclusion : We report good results through surgery of pituitary apoplexy in a clinical and endocrine outcomes. The surgery should be performed as soon as possible to be a suitable method for treating pituitary apoplexy.

• Journal of Veterinary Science
• /
• 제22권5호
• /
• pp.64.1-64.12
• /
• 2021

Background: Pituitary pars intermedia dysfunction (PPID), a neurodegenerative disease leading to reduced dopamine production, is a common disease in aged horses. The treatment is based on administration of the dopamine agonist pergolide. This drug has been related to valvular fibrosis in humans, but the cardiovascular effect of this drug has not yet been investigated in horses. Objectives: To determine whether pergolide induces valvular disease in horses or affects the cardiac function. Methods: Standard, tissue Doppler (TDE) and two-dimensional speckle tracking (STE) echocardiography were performed in horses with diagnosed PPID based on adrenocorticotropic hormone dosage. Measurements taken in horses treated with pergolide were compared with those from untreated horses with nonparametric t-tests. Furthermore, measurements from follow-up examinations performed at least three months after the initial exam were compared with a Wilcoxon signed rank test for repeated measurements in each group. Results: Twenty-three horses were included. None of the 12 horses under treatment developed valvular regurgitation. Furthermore, no differences in the measurements of the left ventricular systolic or diastolic function could be seen between the group of horses with treatment and those without treatment. Measurements taken in the follow-up exam did not differ compared to those taken in the initial exam in both groups. Conclusions: No changes of the left ventricular function assessed by TDE and STE could be shown in a small population of horses with confirmed PPID. Treatment with pergolide did not affect the ventricular function nor induce valvular disease.

• 한국임상약학회지
• /
• 제22권3호
• /
• pp.251-259
• /
• 2012

Ulcerative colitis (UC) is characterized by a life-long chronic course with remissions and exacerbations. Use of biological therapies may reduce or delay the surgical procedures in patients with UC. The aim of this study was to determine the impact of infliximab (IFX) use on the rate of remission, surgical interventions, and the effect on quality of life in patients with moderate to severe UC. Literature was searched for studies that investigated the efficacy of IFX on the rate of remission, colectomy and quality of life (QoL) between January 1990 and June 2012 at MEDLINE, January 1988 and June 2012 at EMbase and others. Eleven trials were included in the meta-analysis; divided into placebo controlled 8 trials and intravenous corticosteroid controlled group 3 trials. In comparison to placebo control groups, patients who received IFX had an odds ratio (OR) of 3.712 (95% CI: 2.714, 5.079) for the short-term clinical remission, and 3.053 (95% CI: 2.044, 4.559) for the rate of long-term remission. In colectomy rate and quality of life (QoL), odds ratio were 0.566(95% CI: 0.387, 0.827) and 0.658 (0.505, 0.811) respectively. Any adverse reactions including infections, infusion reaction, rash and arthralgia were equivalent in both groups. Compared with intravenous corticosteroid controlled group, patients who received IFX had lower remission rate with short-term odds ratio 0.227 (95% CI: 0.033, 1.556) and long-term odds ratio 1.054 (95% CI: 0.317, 3.502) respectively. However, statistical significance was not showed with both two analyses. The higher adverse drug reaction (ADR) rates were occurred in the corticosteroid controlled groups. 73.3% of patients treated corticosteroid reported Cushing-like syndrome with moon face. In conclusion, IFX does increase remission rate and decrease the rate of colectomy in patients with UC without elevating any adverse reactions significantly. IFX also improves QoL in moderate to severe UC patients. It would not exceed the efficacy of intravenous corticosteroid, whereas intravenous corticosteroid also reported high rate of adverse reactions.

• Radiation Oncology Journal
• /
• 제9권2호
• /
• pp.185-195
• /
• 1991

가톨릭의대 강남성모병원 방사선치료실에서는 1983년 3월부터 1990년 4월 사이 7년여 동안에 뇌하수체선종으로 확진되었던 74명의 환자($7\~65$세, 평균 37세, 남:여=39:35)에 대하여 뇌하수체부위에 외부방사선치료를 하였다. 방사선치료는 6 MV 선형 가속기를 사용하여 선원중심축거리 80 cm, $4{\times}4{\times}4\~8{\times}8{\times}8cm^3$ 조사야로 3문조사하였다(180cGy/일, 5회/주, $20\~65$Gy). 5예에서는 정위다방향고선량단일조사($15\~25$ Gy/l회)를 실시하였다. 이 환자들의 수술전후 및 방사선치료 후에 복합뇌하수체자극검사를 실시하여 종양의 호르몬분비에 따른 분류와 방사선치료가 호르몬분비에 미치는 영향을 추적조사하였다. 호르몬분비에 따른 뇌하수체선종의 분류는 프로랙틴종 23예($29\%$), 성장호르몬분비종 20예($26\%$), 부신피질자극호르몬분비종 6예 ($8\%$) (쿠싱병 4예와 넬슨증후군 2예)였으며 4예 ($5\%$)에서는 프로랙틴과 성장호르몬을 동시에 분비하였다. 한편, 호르몬분비기능없는 종양이 29예($37\%$)였다. 23예의 프로랙틴종 중 15예 ($65\%$)와 20예의 성장호르몬분비종 중 3예 ($15\%$)에서는 방사선치료$2\~3$년 후 정상 호르몬 수치로 전환되었다. 부신피질자극호르몬분비종은 6예 중 1예를 제외한 전예에서 치료 후 모두 정상이되었다. 방사선치료에 따른 부작용으로서 범하수체기능저하증 및 갑상선기능저하증이 각각 7예($9\%$)씩 그리고 성선기능저하증 2예 ($3\%$) 등이 관찰되었다. 전예 중 15예 ($20\%$)에서는 정기적인 호르몬 추적검사를 실시하지 못하였다.

• Tuberculosis and Respiratory Diseases
• /
• 제52권5호
• /
• pp.529-538
• /
• 2002

배 경 : 급성 천식발작 치료의 근간을 이루는 전신성 스테이로드는 골다공증, 쿠싱증후군, 당뇨, 고혈압, 출혈성 경향 등의 합병증으로 초기에 흡입용 스테로이드 사용이 추천되고 있다. 흡입성 스테로이드에는 정량분무식 에어로졸(MDI)나 분말형 흡입제(DPI), 무화에어로솔(nebulized aerosol)를 사용해오고 있는데 소아나 노인, 호흡곤란이 아주 심한 성인 환자에서는 무화 에어로졸(nebulized aerosol)을 이용한 budesonide흡입이 효과적일 수 있다. 이에 급성 발작으로 내원한 성인 천식 환자에 nebulized budesonide를 적용했을 때의 임상적인 효과와 스테로이드 보존 효과, 스테로이드의 부작용 중 하나인 시상하부-뇌하수체-부신 축의 이상에 대한 영향을 알고자 하였다. 방 법 : 1. 2000년 6월부터 2001년 9월까지 입원한 기관지 천식, 천식을 동반한 만성 폐질환 환자를 선택하여 1군은 전신성 스테로이드와 nebulized budesonide 2mg을 사용한 군, 2군은 전신성 스테로이드와 budesonide turbuhaler를 사용한 군, 3군은 단지 전신성 스테로이드만을 사용한 군으로 나누고서 최대호기유속, 대기중 동맥혈가스검사, 폐기능검사, 증상지수(호흡곤란, 기침, 야간천식, 천명음), 스테로이드 총량, 입원기간를 기록하여 분석하였다. 2. 내원 10일전부터 어떤 종류의 스테로이드도 쓰지 않았던 환자를 선택하여 budesonide turbuhaler와 nebulized budesonide를 사용한 군으로 나누어 24시간 소변내 코타솔 수치를 측정하여 비교하였다. 결 과 : 1. 임상효과: 순수한 천식환자에서 증상 지수(호흡곤란, 천명음, 기침, 야간천식), 스테로이드 용량, 재원일수, 폐기능 소견, 최대호기유속, 동맥혈가스검사에서 세군간의 차이가 없었고, 천식을 동반한 만성 폐쇄성 폐질환환자를 대상으로 비교했을 때도 세균간의 차이는 없었다. 2. 시상하부-뇌하수체-부진 축의 효과 : nebulizer budesonide 사용군은 turbuhaler 사용군과 마찬가지로 부신축의 억제효과가 있으나 두 군간에 차이는 없었다.(p=0.288) 결 론 : 성인 천식환자에서 급성 발작시 budesonide 형태에 관련없이 전신성 스테로이드만이 치료에 도움을 줄 수 있다는 사실을 확인하였고, 치료 용량의 nebulizer 사용군에서 turbuhaler 사용군과 마찬가지로 시상하부-뇌하수체-부신 축에 대한 억제작용이 있었다.